Get the Weekly Intelligence Brief — top committee picks every Sunday.

ARGX vs LLY

argenx SE vs Eli Lilly and Company — AI-powered side-by-side comparison
ARGX
argenx SE
66
Buy
VS
LLY
Eli Lilly and Company
56
Buy
MetricARGXLLY
AI Score 66 56
Price $1,017.86 $1,238.72
P/E Ratio 36.97× 41.81×
ROE 17.6% 77.8%
Revenue Growth YoY
Gross Margin 89.9% 84.0%
Debt / Equity 0.01× 1.62×
Dividend Yield 0.0% 0.5%
RSI (14) 69.2 59.0
Beta -0.022 0.506
Expected Upside +0.1%

AI Committee View

Current Innellis committee reasoning for ARGX versus LLY.
ARGX leads by 10 points.

ARGX scores 66/100 (Buy) versus LLY at 56/100 (Buy).

ARGX Committee View
67% agreement
6 analysts

The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.

Bull Case
  • ROE of 22.4% shows genuine earnings power backing the valuation — Value
  • Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
  • EPS growing 95.7% YoY — Growth
Bear Case
  • Price-to-book of 6.9x prices in significant intangible value — Value
  • RSI at 84 is in overbought territory — Technical
  • Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
LLY Committee View
67% agreement
6 analysts

The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 49.6% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 1.60) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • ROE of 92.6% shows genuine earnings power backing the valuation — Value
  • Revenue growing 49.6% YoY -- genuine top-line momentum — Growth
  • EPS growing 94.6% YoY — Growth
Bear Case
  • P/E of 43.2 is expensive by classic value standards — Value
  • Price-to-book of 38.3x prices in significant intangible value — Value
  • Debt-to-equity of 1.60 adds balance-sheet risk to the value case — Value
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ARGX Full Analysis LLY Full Analysis